Trial · NCT07893223
Vancomycin Exposure and Biomarker Tracking Using Real-time Monitoring of Interstitial Fluid
NCT07893223, Not yet recruiting, Nutromics
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Vancomycin Exposure and Biomarker Tracking Using Real-time Monitoring of Interstitial Fluid. Trials, record NCT07893223. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07893223
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Vancomycin Exposure and Biomarker Tracking Using Real-time Monitoring of Interstitial Fluid
- NCT number
- NCT07893223
- Status
- Not yet recruiting
- Enrollment
- 200 participants, estimated
- Lead sponsor
- Nutromics
- Conditions
- Biomarkers, Acute Kidney Injury, Sepsis
- First posted
- 2026-10-23
- Last updated
- 2026-10-23
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Accuracy of Device-measured vancomycin ISF concentration vs. paired serum concentration | Up to 5 Days | Comparison of vancomycin concentration-time profiles and pharmacokinetic parameters (Cmax, Tmax, Cmin, AUC0-24) derived from interstitial fluid (Sensor Device) against paired serum vancomycin immunoassay results. |
| Primary | Accuracy of Device-measured biomarker (creatinine, C-reactive protein, lactate) ISF concentration vs. paired serum concentration | Up to 5 days | Determination of accuracy between Device-reported biomarker values and paired serum immunoassay results. |
| Primary | Relationship between ISF analyte concentrations and clinical outcomes | Through 30 days after study completion | Descriptive summary of association between ISF concentration profiles (vancomycin, creatinine, C-reactive protein, lactate) and 30-day clinical outcomes (discharge/readmission, morbidity, mortality, treatment-emergent adverse events). |
| Primary | General performance characterisation of the Device | Up to 5 days | Paired precision between simultaneously worn devices; device accuracy throughout wear duration; electrochemical sensor quality metrics. |
| Secondary | Device performance across patient subgroups | Up to 5 days | Exploratory analysis of Peak Plasma Concentration (Cmax) by demographic and clinical subgroup (age, sex, ethnicity, BMI, medical conditions/pathologies). |
| Secondary | Device performance across patient subgroups | Up to 5 days | Exploratory analysis of Time to Peak Concentration (Tmax) by demographic and clinical subgroup (age, sex, ethnicity, BMI, medical conditions/pathologies). |
| Secondary | Device performance across patient subgroups | Up to 5 days | Exploratory analysis of Minimum Blood Plasma Concentration (Cmin) by demographic and clinical subgroup (age, sex, ethnicity, BMI, medical conditions/pathologies). |
| Secondary | Device performance across patient subgroups | Up to 5 days | Exploratory analysis of Area Under the Curve (AUC0-24) by demographic and clinical subgroup (age, sex, ethnicity, BMI, medical conditions/pathologies). |
| Secondary | Stability and precision of the Device over time, compared to standard laboratory assays | Up to 5 days | Assessment of device reporting accuracy compared to reported values from standard laboratory assays across wear duration, including after 48-hour device replacement. |
| Secondary | Incidence of Adverse Events | From first device application to 30 days post study completion | Frequency, severity and seriousness of adverse reactions associated with the Device; descriptive summary of application-site photographs. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07893223
GET https://conductscience.org/api/trials/v1/NCT07893223/registered